Table 2 Baseline characteristics of the test-retest population

Female sex n (%)

8 (80)

5 (50)

4 (40)

0.266

Age (years)

65 (62–68)

58.5 (49–67)

47 (32–52)

0.005^a

Duration (years)

15.5 (8–24)

8.5 (5–14)

4 (2–6)

0.017^b

DMARD n (%)

9 (90)

9 (90)

2(20)

0.003

Biologics n (%)

6 (60)

7 (70)

8(80)

0.879

DAS28-CRP

3.9 (3.7–4.2)

3.7 (3.1–4.4)

-

0.519

TJC 28

5.5 (4–10)

6 (2–9)

-

0.791

SJC 28

1 (1–4)

0 (0–0)

-

0.020

BASDAI (0–100)

-

67 (34–83)

28 (14–43)

0.364

BASFI (0–100)

-

60.5 (37–89)

18 (13–32)

0.212

ASDAS

-

3.05 (2.4–3.8)

2.1 (1.1–2.7)

0.104

VAS pain mm

43 (26–53)

61.5(25–73)

24.5 (19–41)

0.331

VAS fatigue mm

65 (40–79)

63.5 (32–82)

43 (26–67)

0.397

VAS global mm

50 (34–63)

72 (32–87)

29.5 (22–57)

0.219

HAQ

1.25 (0.875–2)

-

-

-

Crp mg/l

5.5 (1–10)

4 (1–8)

3.5 (1–9)

0.939

HLA-B27 n (%)

-

2(100)(n = 2)

3(75)(n = 4)

1

IgM-RF n (%)

5(50)

-

-

-

Anti-CCP n (%)

5(50)

-

-

-